54751-93-8Relevant academic research and scientific papers
5-AMINOPYRAZOLE CARBOXAMIDE DERIVATIVE AS BTK INHIBITOR AND PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION THEREOF
-
Paragraph 0058, (2019/04/16)
The present application discloses novel 5-aminopyrazole carboxamide compounds as shown in formula (I), and stereoisomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof. In addition, the present application further discloses a method for the preparation of the compounds, a pharmaceutical composition comprising a compound of the invention and the use of the compounds.
Investigation of orexin-2 selective receptor antagonists: Structural modifications resulting in dual orexin receptor antagonists
Skudlarek, Jason W.,DiMarco, Christina N.,Babaoglu, Kerim,Roecker, Anthony J.,Bruno, Joseph G.,Pausch, Mark A.,O'Brien, Julie A.,Cabalu, Tamara D.,Stevens, Joanne,Brunner, Joseph,Tannenbaum, Pamela L.,Wuelfing, W. Peter,Garson, Susan L.,Fox, Steven V.,Savitz, Alan T.,Harrell, Charles M.,Gotter, Anthony L.,Winrow, Christopher J.,Renger, John J.,Kuduk, Scott D.,Coleman, Paul J.
, p. 1364 - 1370 (2017/03/08)
In an ongoing effort to explore the use of orexin receptor antagonists for the treatment of insomnia, dual orexin receptor antagonists (DORAs) were structurally modified, resulting in compounds selective for the OX2R subtype and culminating in the discovery of 23, a highly potent, OX2R-selective molecule that exhibited a promising in vivo profile. Further structural modification led to an unexpected restoration of OX1R antagonism. Herein, these changes are discussed and a rationale for selectivity based on computational modeling is proposed.
Bis(difluoromethyl)trimethylsilicate Anion: A Key Intermediate in Nucleophilic Difluoromethylation of Enolizable Ketones with Me3SiCF2H
Chen, Dingben,Ni, Chuanfa,Zhao, Yanchuan,Cai, Xian,Li, Xinjin,Xiao, Pan,Hu, Jinbo
supporting information, p. 12632 - 12636 (2016/10/31)
A pentacoordinate bis(difluoromethyl)silicate anion, [Me3Si(CF2H)2]?, is observed for the first time by the activation of Me3SiCF2H with a nucleophilic alkali-metal salt and 18-crown-6. Further study on its reactivity by tuning the countercation effect led to the discovery and development of an efficient, catalytic nucleophilic difluoromethylation of enolizable ketones with Me3SiCF2H by using a combination of CsF and 18-crown-6 as the initiation system. Mechanistic investigations demonstrate that [(18-crown-6)Cs]+[Me3Si(CF2H)2]?is a key intermediate in this catalytic reaction.
Identification of MK-8133: An orexin-2 selective receptor antagonist with favorable development properties
Kuduk, Scott D.,Skudlarek, Jason W.,Dimarco, Christina N.,Bruno, Joseph G.,Pausch, Mark H.,O'brien, Julie A.,Cabalu, Tamara D.,Stevens, Joanne,Brunner, Joseph,Tannenbaum, Pamela L.,Garson, Susan L.,Savitz, Alan T.,Harrell, Charles M.,Gotter, Anthony L.,Winrow, Christopher J.,Renger, John J.,Coleman, Paul J.
, p. 2488 - 2492 (2015/06/02)
Abstract Antagonism of orexin receptors has shown clinical efficacy as a novel paradigm for the treatment of insomnia and related disorders. Herein, molecules related to the dual orexin receptor antagonist filorexant were transformed into compounds that w
Discovery of piperidine ethers as selective orexin receptor antagonists (SORAs) inspired by filorexant
Raheem, Izzat T.,Breslin, Michael J.,Bruno, Joseph,Cabalu, Tamara D.,Cooke, Andrew,Cox, Christopher D.,Cui, Donghui,Garson, Susan,Gotter, Anthony L.,Fox, Steven V.,Harrell, C. Meacham,Kuduk, Scott D.,Lemaire, Wei,Prueksaritanont, Thomayant,Renger, John J.,Stump, Craig,Tannenbaum, Pamela L.,Williams, Peter D.,Winrow, Christopher J.,Coleman, Paul J.
, p. 444 - 450 (2015/01/30)
Highly selective orexin receptor antagonists (SORAs) of the orexin 2 receptor (OX2R) have become attractive targets both as potential therapeutics for insomnia as well as biological tools to help further elucidate the underlying pharmacology of the orexin signaling pathway. Herein, we describe the discovery of a novel piperidine ether 2-SORA class identified by systematic lead optimization beginning with filorexant, a dual orexin receptor antagonist (DORA) that recently completed Phase 2 clinical trials. Changes to the ether linkage and pendant heterocycle of filorexant were found to impart significant selectivity for OX2R, culminating in lead compound PE-6. PE-6 displays sub-nanomolar binding affinity and functional potency on OX2R while maintaining >1600-fold binding selectivity and >200-fold functional selectivity versus the orexin 1 receptor (OX1R). PE-6 bears a clean off-target profile, a good overall preclinical pharmacokinetic (PK) profile, and reduces wakefulness with increased NREM and REM sleep when evaluated in vivo in a rat sleep study. Importantly, subtle structural changes to the piperidine ether class impart dramatic changes in receptor selectivity. To this end, our laboratories have identified multiple piperidine ether 2-SORAs, 1-SORAs, and DORAs, providing access to a number of important biological tool compounds from a single structural class.
BRUTON'S TYROSINE KINASE INHIBITORS
-
Page/Page column 150, (2014/05/24)
Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (BTK). Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the BTK inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. (Formula I)
ACETOXYLATION OF PIPERIDINE DERIVATIVES AT THE 3-POSITION. STEREOSELECTIVE SYNTHESIS OF PSEUDOCONHYDRINE AND N-METHYLPSEUDOCONHYDRINE
Shono, Tatsuya,Matsumura, Yoshihiro,Onomura, Osamu,Kanazawa, Takenobu,Habuka, Masahiro
, p. 1101 - 1104 (2007/10/02)
Anodic oxidation of N-methoxycarbonylpipridine derivatives in AcOH gave 2,3-diacetoxylated products, which were shown to be useful intermediates for the stereoselective synthesis of 3-hydroxypiperidine derivatives including pseudoconhydrine and N-methylpseudoconhydrine, the Conium alcaloids.
